Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands Updates PediaCare NDC Information A Year After Sale

Executive Summary

The OTC drugs and personal care products company will correct Structured Product Labeling information in the US NDC Directory for PediaCare Children’s Plus Multi-Symptom Cold and Children’s Plus Flu to include one of the products' active ingredient, phenylephrine.

You may also be interested in...



Moberg Sustains Derma Drive, Acquires Prestige Brands' New Skin

The Swedish firm pays $40m for the PediaCare and Fiber Choice brands in addition to New Skin Liquid Bandages, which are available in spray and liquid delivery and are "the main profitability contributor in the acquired portfolio," says CEO Peter Wolpert.

Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition

On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch

Safe Use Of Hydrogen-Peroxide Contact Lens Solution Magnified in US FDA Draft Guidance

Draft guidance pulls from Ophthalmic Devices Panel and Risk Communication Advisory Committee 2017 meeting to discuss more clearly communicating risks of the solutions to consumers while allowing products to remain available OTC.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel